Healthcare provider profile · identity verified

Timothy Chandler, D.O.

Internal Medicine · LANCASTER, CA · NPI 1740433622

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	482	183
Lisinopril	Lisinopril	302	121
Amlodipine Besylate	Amlodipine Besylate	272	101
Losartan Potassium	Losartan Potassium	232	88
Rosuvastatin Calcium	Rosuvastatin Calcium	208	84
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	199	41
Levothyroxine Sodium	Levothyroxine Sodium	194	69
Metformin Hcl	Metformin Hcl	186	73
Gabapentin	Gabapentin	169	78
Pantoprazole Sodium	Pantoprazole Sodium	158	45
Albuterol Sulfate Hfa	Albuterol Sulfate	153	85
Omeprazole	Omeprazole	148	64
Ozempic	Semaglutide	146	28
Ibuprofen	Ibuprofen	131	61
Glipizide	Glipizide	110	47
Simvastatin	Simvastatin	105	39
Atenolol	Atenolol	99	38
Metoprolol Tartrate	Metoprolol Tartrate	97	39
Meloxicam	Meloxicam	92	41
Prednisone	Prednisone	84	72
Tizanidine Hcl	Tizanidine Hcl	75	22
Azelastine Hcl	Azelastine Hcl	74	22
Potassium Chloride	Potassium Chloride	74	33
Trazodone Hcl	Trazodone Hcl	74	33
Hydrochlorothiazide	Hydrochlorothiazide	73	31
Pradaxa	Dabigatran Etexilate Mesylate	72	28
Furosemide	Furosemide	71	26
Tamsulosin Hcl	Tamsulosin Hcl	71	34
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	69	27
Ezetimibe	Ezetimibe	67	24
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	67	24
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	65	11
Terazosin Hcl	Terazosin Hcl	65	23
Metformin Hcl Er	Metformin Hcl	63	30
Montelukast Sodium	Montelukast Sodium	61	29
Jardiance	Empagliflozin	60	21
Allopurinol	Allopurinol	57	21
Clopidogrel	Clopidogrel Bisulfate	51	19
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	51	17
Fluticasone Propionate	Fluticasone Propionate	50	22
Wixela Inhub	Fluticasone Propion/Salmeterol	50	27
Duloxetine Hcl	Duloxetine Hcl	45	17
Triamcinolone Acetonide	Triamcinolone Acetonide	45	31
Bisoprolol Fumarate	Bisoprolol Fumarate	40	18
Fluoxetine Hcl	Fluoxetine Hcl	40	14
Topiramate	Topiramate	40	21
Famotidine	Famotidine	38	18
Hydralazine Hcl	Hydralazine Hcl	38	19
Spiriva Respimat	Tiotropium Bromide	38	11
Humulin N Kwikpen	Insulin Nph Human Isophane	36	13
Ondansetron Hcl	Ondansetron Hcl	35	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	35	15
Carvedilol	Carvedilol	34	15
Tramadol Hcl	Tramadol Hcl	33	11
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	32	12
Hydrocortisone	Hydrocortisone	30	17
Morphine Sulfate Er	Morphine Sulfate	30	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	29	24
Finasteride	Finasteride	29	suppressed
Sertraline Hcl	Sertraline Hcl	29	12
Humulin N	Insulin Nph Human Isophane	28	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	27	11
Ropinirole Hcl	Ropinirole Hcl	27	11
Alendronate Sodium	Alendronate Sodium	26	11
Metoprolol Succinate	Metoprolol Succinate	26	11
Pioglitazone Hcl	Pioglitazone Hcl	26	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	25	suppressed
Terbinafine Hcl	Terbinafine Hcl	25	19
Acyclovir	Acyclovir	24	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	24	suppressed
Mirtazapine	Mirtazapine	24	suppressed
Ondansetron Odt	Ondansetron	23	11
Alvesco	Ciclesonide	22	11
Arexvy	Rsvpref3 Antigen/As01e/Pf	22	22
Eliquis	Apixaban	22	suppressed
Buspirone Hcl	Buspirone Hcl	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	12
Myrbetriq	Mirabegron	21	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	21	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	19
Pravastatin Sodium	Pravastatin Sodium	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	19	suppressed
Lidocaine	Lidocaine	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	18
Benazepril Hcl	Benazepril Hcl	18	suppressed
Humalog	Insulin Lispro	18	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	18	16
Azithromycin	Azithromycin	17	17
Breyna	Budesonide/Formoterol Fumarate	17	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Naproxen	Naproxen	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Lactulose	Lactulose	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	16	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	15	15
Citalopram Hbr	Citalopram Hydrobromide	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Victoza 2-Pak	Liraglutide	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	12
Estradiol	Estradiol	13	suppressed
Fluconazole	Fluconazole	13	12
Humulin R	Insulin Regular, Human	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	12	suppressed
Fentanyl	Fentanyl	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Podofilox	Podofilox	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error